Clinical Trials on Lymphoma, B-Cell in Netherlands

Total 1556 results

University Medical Center Groningen
Hoffmann-La Roche; Amsterdam UMC, location VUmc; Stichting Hemato-Oncologie voor...

Withdrawn

Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Netherlands
Stichting Hemato-Oncologie voor Volwassenen Nederland

Recruiting

Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse (HOVON 136 NHL)

DLBCL

Netherlands
Gustave Roussy, Cancer Campus, Grand Paris
Children's Oncology Group

Unknown

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

B-cell Non Hodgkin Lymphoma | Mature B-cell Leukemia Burkitt-type

Belgium, France, United Kingdom, Netherlands, Canada, Hungary, Italy, Poland, Spain, China
University Medical Center Groningen
Stichting Hemato-Oncologie voor Volwassenen Nederland

Recruiting

Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL (HOVON161)

NHL | DLBCL - Diffuse Large B Cell Lymphoma

Netherlands
University Medical Center Groningen

Recruiting

PD-L1 PET-imaging During CAR T-cell Therapy

Large B-cell Lymphoma

Netherlands
The Netherlands Cancer Institute
Dutch Cancer Society

Completed

To Decrease Fatigue With Light Therapy (SPARKLE)

Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma

Netherlands
Genmab
AbbVie

Terminated

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Small Lymphocytic Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B-cell Lymphoma

United States, Spain, Netherlands, Belgium, France, Denmark
Genentech, Inc.

Completed

A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma

Chronic Lymphocytic Leukemia | Non-Hodgkins Lymphoma

United States, France, Canada, Netherlands
TG Therapeutics, Inc.

Terminated

Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma

United States, Poland, Australia, Italy, United Kingdom, Israel, Korea, Republic of, Slovakia, Spain
Nurix Therapeutics, Inc.

Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Primary Central Nervous System Lymphoma (PCNSL) | Marginal Zone Lymphoma (MZL) | Waldenstrom Macroglobulinemia (WM) | Diffuse Large B Cell Lymphoma (DLBCL)

United States, United Kingdom, Netherlands
UMC Utrecht
Julius Clinical

Not yet recruiting

Mitochondrial dysfUnction: a Key Player in Doxorubicin-induced Skeletal and Cardiac muscLE Damage (MUSCLE)

B-cell Lymphoma | Chemotherapeutic Toxicity | T-cell Lymphoma | Doxorubicin Induced Cardiomyopathy

Netherlands
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement

Diffuse Large B-cell Lymphoma

Netherlands, United Kingdom, Italy, Czechia
Amgen
Merck Sharp & Dohme LLC

Completed

Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) (HARBOUR)

Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

United States, Germany, Spain, Australia, Netherlands, France
Novartis Pharmaceuticals

Completed

Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma (COEB071X2103)

CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma

Taiwan, Italy, Netherlands, Hong Kong, Germany, United States, Korea, Republic of, France
Kite, A Gilead Company

Active, not recruiting

Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)

Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Spain, United States, Czechia, Sweden, Germany, Belgium, Italy, Canada, France, Netherlands, Poland
Stichting Hemato-Oncologie voor Volwassenen Nederland
UMC Utrecht; Amsterdam University Medical Centers; The Dutch Network for Cardiovascular...

Not yet recruiting

Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma (HO170DLBCL)

DLBCL - Diffuse Large B Cell Lymphoma

Netherlands
Kite, A Gilead Company

Completed

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)

Relapsed Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B Cell Lymphoma (DLBCL) | Transformed Follicular Lymphoma (TFL) | Primary Mediastinal B-cell Lymphoma (PMBCL) | High Grade B-cell Lymphoma (HGBCL)

United States, Netherlands, Canada, France, Germany, Israel
Genmab
AbbVie

Active, not recruiting

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1)

Small Lymphocytic Lymphoma (SLL) | DLBCL | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | MCL | Marginal Zone Lymphoma (MZL) | High-grade B-cell Lymphoma (HGBCL) | FL

Korea, Republic of, United States, Australia, Singapore, Netherlands, Sweden, France, Finland, United Kingdom, Spain, Germany, Denmark, Italy, Poland, Canada
Gustave Roussy, Cancer Campus, Grand Paris
Children's Oncology Group

Active, not recruiting

Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation

Primary Mediastinal Large B Cell Lymphoma

France, Belgium, United Kingdom, Netherlands, Canada, Hungary, Italy, Poland, Spain
Kite, A Gilead Company

Recruiting

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

Relapsed and/or Refractory B-cell Lymphoma

United States, Netherlands, United Kingdom, Germany
Miltenyi Biomedicine GmbH
ICON plc

Recruiting

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (DALY 2-EU)

Diffuse Large B-cell Lymphoma

Spain, Germany, Netherlands, Belgium, France, Czechia, Austria, Lithuania, Sweden, Hungary, Italy, Poland
Celgene

Completed

A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

Lymphoma, Non-Hodgkin | Precursor Cell Lymphoblastic Leukemia-Lymphoma

Spain, Netherlands, United States, France, Germany, Italy
Janssen Research & Development, LLC

Terminated

An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Mantle-Cell

United States, Australia, France, Belgium, Turkey, Netherlands, Korea, Republic of
Novartis Pharmaceuticals

Terminated

Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

Taiwan, Netherlands, Hong Kong, Italy, Germany, United States, Spain, France, United Kingdom, Korea, Republic of
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients (JULIET)

Diffuse Large B-cell Lymphoma (DLBCL)

United States, Japan, Australia, Italy, Canada, Germany, Norway, Netherlands, France, Austria
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

Lymphoma

United States, Spain, France, Netherlands, Poland, Denmark
Stichting Hemato-Oncologie voor Volwassenen Nederland

Active, not recruiting

DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL (HO152)

Lymphoma, B-Cell | Non Hodgkin Lymphoma | High-grade B-cell Lymphoma | MYC Translocation | BCL-2 Translocation

Netherlands, Belgium
Bristol-Myers Squibb

Completed

Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)

Lymphoma. Non-Hodgkin

Germany, Italy, United States, Spain, Netherlands, Australia, United Kingdom, Belgium, France, Canada, Sweden, Singapore
ADC Therapeutics S.A.

Recruiting

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5)

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

Japan, Belgium, France, Italy, Spain, United Kingdom, United States, Israel, Hungary, Brazil, Switzerland, Poland, Canada, Puerto Rico, Czechia, Netherlands, China, Mexico, Argentina, Chile, Turkey
Spectrum Pharmaceuticals, Inc

Terminated

Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy

Diffuse Large B-cell Lymphoma | Follicle Center Lymphoma

United States, France, United Kingdom, Ireland, Israel, Belgium, Spain, Netherlands, Australia, Puerto Rico, Canada, Italy, Austria
Genmab
AbbVie

Active, not recruiting

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL (EPCORE DLBCL-1)

Diffuse Large B-cell Lymphoma

Korea, Republic of, Spain, Taiwan, Belgium, France, Israel, United Kingdom, China, United States, Netherlands, Japan, Sweden, Turkey, Australia, Singapore, Germany, Denmark, Poland, Italy, Hungary, Austria, Russian Federation, Norway, Canad... and more
Genentech, Inc.

Completed

A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (ROMULUS)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma

United States, Canada, France, Italy, Germany, Netherlands
Biomea Fusion Inc.

Recruiting

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

Lymphoma | Lymphoma, Non-Hodgkin | Acute Myeloid Leukemia | Cancer | Progression | Multiple Myeloma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Plasma Cell Myeloma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Refractory | Myeloma, Plasma-Cell | Myelomatosis | Acute Mixed-Phenotype...

United States, Spain, Netherlands, Greece, Italy
Kite, A Gilead Company

Active, not recruiting

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

United States, Spain, United Kingdom, Canada, Netherlands, Germany, France, Sweden, Israel, Switzerland, Belgium, Australia, Austria, Italy
Celgene

Completed

A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.

Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin

France, Italy, Netherlands
Genmab
AbbVie

Recruiting

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (EPCORE™ NHL-2)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma

United States, France, Italy, Spain, United Kingdom, Belgium, Denmark, Netherlands, Finland, Czechia, Sweden, Australia, Norway
Hoffmann-La Roche

Completed

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Lymphoma

United States, Italy, Korea, Republic of, Australia, Canada, Czechia, Spain, United Kingdom, France, Germany, Hungary, Turkey, Netherlands
Seagen Inc.

Active, not recruiting

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL (ECHELON-3)

Diffuse Large B-cell Lymphoma

United States, France, Australia, Czechia, Italy, Spain, Canada, Belgium, Korea, Republic of, United Kingdom, Poland, Denmark, Germany, Netherlands, Switzerland, Taiwan
Hoffmann-La Roche

Completed

A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a

Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma

Hong Kong, Germany, Philippines, Taiwan, Turkey, Canada, Australia, Austria, New Zealand, Thailand, Hungary, Italy, Korea, Republic of, Romania, Netherlands, Brazil, Indonesia, Croatia, Egypt, Portugal, Sweden, Colombia, Argentina, De... and more
Karyopharm Therapeutics Inc

Recruiting

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

United Kingdom, United States, Australia, Austria, Belgium, Bulgaria, Canada, France, Germany, Greece, Hungary, India, Israel, Italy, Netherlands, New Zealand, Poland, Serbia, Spain
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART C)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Netherlands
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Recruiting

HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies (HEM-iSMART D)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Netherlands
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Withdrawn

HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART A)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Netherlands
Merus N.V.
Incyte Corporation

Recruiting

A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

Advanced Cancer | Solid Tumor, Adult | B-cell Lymphoma, Adult

United States, Spain, Belgium, Netherlands
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART B)

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic...

Netherlands
AstraZeneca

Completed

Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Chronic Myelomonocytic Leukemia | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | High Risk Myelodysplastic Syndrome | Small Lymphocytic Lymphoma | B-cell Non-Hodgkin Lymphoma | Richter's Syndrome | T-cell Non-Hodgkin Lymphoma | Relapsed or Refractory...

United Kingdom, Germany, Netherlands
Hoffmann-La Roche

Completed

A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

Italy, Belgium, Canada, Finland, Ireland, Netherlands, Peru, Spain, United Kingdom, Venezuela, Russian Federation, Brazil, France, Poland, Israel, South Africa, Thailand, Bulgaria, Colombia, Greece, Turkey, Argentina, Saudi Arabia, Uk... and more
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Lymphoma

United States, Australia, France, Poland, United Kingdom, China, Belgium, Germany, Spain, Israel, Turkey, Ukraine, Japan, Taiwan, Canada, Denmark, Finland, Korea, Republic of, Netherlands, Brazil, Russian Federation, Argentina, Norway, Swed... and more
GlaxoSmithKline

Completed

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma (ORCHARRD)

Lymphoma, Large-Cell, Diffuse

United States, Netherlands, Estonia, Spain, United Kingdom, Sweden, Israel, Poland, Belgium, Korea, Republic of, Singapore, Austria, Germany, Finland, Ireland, Thailand, China, Russian Federation, Czech Republic, Argentina, Denmark and more
Regeneron Pharmaceuticals

Recruiting

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Participants With Aggressive B-cell Non-Hodgkin Lymphomas (ATHENA-1)

B-cell Non-Hodgkins Lymphoma (B-NHL)

United States, Spain, United Kingdom, Netherlands

Clinical Trials on Lymphoma, B-Cell in Netherlands

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations